Pitchers

Home » Pitchers

Start-up Slams

Thursday, December 10^th | 11.30 am – 12.30 pm

DIAGNOSTICS & PREVENTION

AMK Biotech Seed
Tissu histology – AI-based analysis – Tissue profiling

MultivisionDx Seed
Spatial biology diagnostics – AI powered biomarker discovery – Digital pathology

DAMOCLES Diagnostics Series A
AMR – Rapid AST – Bacteria

CARDIOVASCULAR & METABOLIC DISEASES

Revadix Pre-seed / Seed
EPAC-1 – Cardiovascular – Small molecule

Flavolife Series A
Senolytics – Acute kidney injury / AKD – First-in-class small molecule

Thursday, December 10^th | 2.00 – 3.30 pm

RESEARCH TOOLS & ENABLING TECHNOLOGY PLATFORMS

UNIINK Pre-seed
Cell therapy – Cell encapsulation – 3D bioprinting

bYoRNA Seed
mRNA – Bioproduction – saRNA

Nocturna Therapeutics Seed
circRNA – RNA Therapeutics – ALS

KinCon biolabs Seed
Cellular target engagement – Protein Conformation – Targeted protein degradation

Leafycoll Seed
Proteins – Bioengineering – Plants

Fluosphera Series A
3D Cell Culture – Transferable – Scalable

DRUG DISCOVERY, DEVELOPMENT & DELIVERY

ExCulture Seed / Series A
Mixed Cultures – Sulfated glycosaminoglycans – Patented Technology

Thursday, December 10^th | 5.15 – 6.00 pm

Introduction: Benjamin Hall, Director and Head of the Circuit Biology Department, Lundbeck

CNS DISORDERS

CREATe Therapeutics Pre-seed / Seed
Gene therapy – Chemogenetics – Epilepsy

PepTiDa Seed
Selective JNK3 inhibitor – Stroke neuroprotection – Plasma JNK3 biomarker

Friday, December 11^th | 9.15 – 11.00 am

Introduction: Prabhu Velusami, Senior Director Search and Evaluation, External Scientific Innovation, Johnson & Johnson

RESPIRATORY DISEASES

AATec Medical Series A
Respiratory – Bronchiectasis COPD – Lung diseases

ONCOLOGY & IMMUNO-ONCOLOGY

Chemteios Biologics Pre-seed
Migrastatic – Metastasis – Preventative Therapy

Solid IO Seed
Functional precision medicine – Treatment response prediction – Immuno-Oncology

SEE2CURE Seed
Fluorescence-guided surgery – Tumor-specific biomarker – Precision surgical oncology

Blue Bees Therapeutics Series A
Immuno-Oncology – Immunotherapy – Biologic

Friday, December 11^th | 11.30 am – 12.30 pm

INFECTIOUS DISEASES & VACCINES

AegiSome Bio Pre-seed
Antimicrobial resistance – Cystic fibrosis – Synthetic cells

Mucovac Pre-seed / Seed
Antimicrobial resistance – Prevention – Gut health

Lovaltech Seed / Series A
Mucoadhesive excipient – Nasal vaccine – Payload-agnostic platform

LivingMed Biotech Seed / Series A
Oral mucosal vaccine – Mucosal immunity – Mircobiome

Research & Licensing Partnerships

Thursday, December 10^th | 10.00 – 11.00 am

RESEARCH TOOLS & ENABLING PLATFORMS

Theorema – Causal Disease Models Early innovation (Prototype with Proof of Concept)
Causal disease modelling – Target discovery and validation – Drug discovery partnerships

Askleia – Free Flow Electrophoresis Translational Development (Prototype with Proof of Concept > Preclinical validation)
Free-Flow Electrophoresis – Bioproduction – Downstream process

Biotech One – EncapX® Translational Development (Prototype with Proof of Concept > Preclinical validation)
Lipid nanoparticles (LNPs) – Nanoliposomes – RNA / mRNA delivery

Fraunhofer IZI – Low Energy Electron Irradiation Translational Development (Prototype with Proof of Concept > Preclinical validation)
Vaccines – Pathogen inactivation – Vaccine manufacturing

Thursday, December 10^th | 5.15 – 6.00 pm

CNS DISORDERS

Vall d’Hebron Research Institute – NeuroMelDx Translational Development (Prototype with Proof of Concept > Preclinical validation)
Parkinson’s Disease – Early detection – Fluid biomarkers

RARE & GENETIC DISEASES

Vall d’Hebron Research Institute – NanoERT Translational Development (Prototype with Proof of Concept > Preclinical validation)
Enzyme Replacement Therapy – Lysosomal storage diseases – Nanotechnology-based platform

Friday, December 11^th | 9.15 – 11.00 am

INFLAMMATORY & AUTOIMMUNE DISEASES

Italian Institute for Genomic Medicine – GAVTX Early innovation (Prototype with Proof of Concept)
Eosinophilic esophagitis (EoE) – Drug-discovery Platform – Oral small molecules

KGH Human – Nail & Skin Topical solution Translational Development (Prototype with Proof of Concept > Preclinical validation)
Regeneration – Safety – Unmeet need

RESPIRATORY DISEASES

RISE/University of Liège – NbE201 Translational Development (Prototype with Proof of Concept > Preclinical validation)
Neutrophil elastase – Single-domain antibody – Acute exacerbations

Friday, December 11^th | 11.30 am – 12.30 pm

INFECTIOUS DISEASES & VACCINES

Institute for Bioengineering of Catalonia – Bacbomb Early innovation (Prototype with Proof of Concept)
Immunoprophylaxis – Antimicrobial Resistance (AMR) – Host-Directed Therapy

Friday, December 11^th | 2.00 – 3.00 pm

ONCOLOGY & IMMUNO-ONCOLOGY

University of Southern Denmark – RAS Splice-Switching Oligonucleotide Platform Early innovation (Prototype with Proof of Concept)
Cancer – RNA – Platform

Istituto Europeo di Oncologia – NovaRNA Translational Development (Prototype with Proof of Concept > Preclinical validation)
mRNA vaccine – UTR engineering – Immune response

DIAGNOSTICS & PREVENTION

Institute for Bioengineering of Catalonia – XpertBiofilm Translational Development (Prototype with Proof of Concept > Preclinical validation)
Biofilm diagnostics – Antimicrobial susceptibility testing – Personalised infection management

Institute for Bioengineering of Catalonia – Precision Therapeutics Translational Development (Prototype with Proof of Concept > Preclinical validation)
Functional precision medicine – Anticancer treatment – Personalised medicine

Animal Health Presentations

Co-organised by: within

Supported by:

Thursday, December 10^th | 4.00 – 5.00 pm

imec-WAVES (Ghent University) Stage 2: POC in vitro
Injectable in-body sensing – Early colic detection – Equine health monitoring

Mouse Data Stage 3: POC in vivo
Artificial intelligence – Behavioral phenotyping – Preclinical research

NanoVet Biotech Stage 3: POC in vivo
Nanobodies – Companion animal health – Half-life extension

PawGenX Stage 3: POC in vivo
Disease-modifying osteoarthritis therapy – Companion animal therapeutic – Small-molecule repurposing

Keragenix Biotech Stage 4: candidates produced at medium scale
Safety – Innovation – Impact

Farzad Abdi-Dezfuli, Partner, Sarsia
Sofia Arnal, Associate, AdBio Partners
Juri Bach, Senior Investment Manager, High-Tech Gründerfonds
Jürgen Bauer, Deputy Managing Director, EMBLEM Technology Transfer
Fadwa Benkessou, Academia-Industry Alliance Manager, Karolinska Institutet
Leonardo Biondi, CEO, Biondi
Jean-Luc Chagnaud, Head of Business Development in Health Innovations, Aquitaine Science Transfert
Martial Descoutures, Head of Pharma and Biotech/Medtech, Corporates & Markets, ODDO BHF
Guy Hélin, CEO, Syngulon
Andreas Kastenbauer, Partner, MIG Capital
Esther Lange, BD Manager Viral Vector Out-Licensing, Revvity
Radoslaw Lipinski, Deputy Head Partnership CNS and NCE, Global BD&L, Boehringer Ingelheim
Julie Proft, Head of Project Management, IOCB Tech
Nicolas Roberti de Winghe, Managing Partner, TCD Capital
Stefan Savic, CEO, LIFE BioCEEd
Daniel Sieiro, Associate, Sofinnova Partners
Yannick Vancoppenolle, Partner, Vives Partners
Giulia Vestri, Partner, Claris Ventures
Joachim Vogt, Director Search and Evaluation, International, Abbvie
Anela Vukoja, Life Sciences investor
Jean-Pascal Marc, General Manager, Ceanothus Consulting
Steve Nanchen, Senior Director – Head External Innovation, Elanco Animal Health
Eduardo De Oliveira Pontes, Director Research Alliances – External Innovation, Zoetis
Hervé Poulet, Senior Director, Strategic Partnering, Boehringer Ingelheim Animal Health
Edouard Timsit, Director of Global Innovation Livestock Health and Sustainability, Ceva Animal Health